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Apoptosis induction and micronuclei formation were compared following cytotoxic treatments in two rat glioma differing in p53
integrity. In vitro, micronuclei emergence but not apoptosis was linked to the p53 mutated status. In vivo, micronuclei assays were
more sensitive to evaluate DNA damage induced by chemotherapy in a p53-mutated solid tumour.
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Most anticancer agents exert their action by triggering apoptosis
(Mow et al, 2001). The product of the tumour-suppressor gene p53
is a key mediator in this process (Soussi, 2000). In normal cells,
wild-type p53 either arrests cell proliferation until the genetic
damage is repaired or forces the cell to commit apoptosis (Cadwell
and Zambetti, 2001). In cancer cells, where p53 alleles are often
mutated, decrease in apoptosis can be compensated by the process
of mitotic catastrophe, a form of cell death resulting from
abnormal mitosis and leading to the formation of cells with
multiple micronuclei (MN) (Roninson et al, 2001). This study
aimed to compare induction of apoptosis and MN formation after
chemo- or radiotherapy, in vitro in two rat glioma cell lines
differing in p53 integrity, the 9L expressing a mutated p53 gene
and the C6 the wild-type gene, and in vivo on established 9L solid
tumours.
MATERIALS AND METHODS
Animals and cell lines
All experiments on Fischer 344 rats have been carried out with
local ethical committee approval and met the standards required
by the UKCCCR guidelines (Workman et al, 1998). The 9L
gliosarcoma cell line and the C6 glioblastoma cell line were
maintained in complete medium, RPMI 1640 supplemented with
10% fœtal calf serum, 1% L-glutamine, 1% sodium pyruvate, 1%
nonessential amino acids, 100IUml
 1 penicillin and 100mgml
 1
streptomycin.
In vitro and in vivo radio- or chemotherapy
For in vitro treatments, 9L and C6 cells were g-irradiated (80Gy,
137Cs irradiator) or treated for 2h with chemotherapeutic drugs
and recultured during 24 or 72h for apoptosis tests or 4h for MN
assays. For in vivo treatments, tumour-bearing rats (10
59L s.c. at
day 0) received i.p. injections of cisplatin (1mgkg
 1), or were
irradiated locally at the tumour site (20Gy) at days 4, 11 and 18
and were killed the day after. The tumours were then dissected and
prepared distinctly for apoptosis or MN assays.
Apoptosis assays
Analysis of caspase 3 activity Caspase-3 activation was measured
in vitro by the cleavage of a specific fluorogenic substrate (Ac-
DEVD-AMC, BD Biosciences, Erembodegem, Belgium). Briefly, 24
or 72h after treatment, cells were lysed and incubated first in
protease buffer and then for 2h at 371C with Ac-DEVD-AMC
substrate (1mgml
 1). The enzyme-catalysed release of fluorescent
AMC was measured, by referring to a standard curve, with a
fluorimeter, at 380nm excitation and 440nm emission wave-
lengths.
Measurement of phosphatidylserine translocation using Annex-
inV–FITC Phosphatidylserine outer translocation on treated
cells was detected by flow cytometry (BD FACScan and CellQuest
software) using AnnexinV–FITC binding (1mgml
 1) (BD Bios-
ciences) and PI (2mgml
 1) counterstaining.
TUNEL assay Treated tumours excised from rats were directly
cryo-preserved in OCT, cut into 10-mm-thick sections and kept at
 201C. Paraformaldehyde 4% fixed tissue sections were permea-
bilised in PBS–Triton X-100 1% solution and incubated for 1h at
371C with TdT enzyme (In Situ Cell Death Detection, Roche
Molecular Biochemicals, Brussels, Belgium) able to add fluores-
cein-conjugated nucleotides to the free 30 ends of DNA fragments
generated in apoptotic cells. Slides were analysed under fluores-
cence microscopy. Received 20 May 2003; revised 4 June 2003; accepted 4 June 2003
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sMicronucleus assay Micronuclei (MN) are detected in cells that
have completed nuclear division following a method developed by
Fenech (2000) that identifies such cells by their binucleate (BN)
appearance after blocking cytokinesis with cytochalasin-B. Briefly,
in vitro treated 9L or C6 cells were incubated with cytochalasin-B
(3mgml
 1) for 24h. Ex vivo resected treated 9L tumours were first
dissociated in DNAse/collagenase solution and recultured before
cytochalasin-B was added. After a hypotonic shock in 0.075 M KCl,
cells were stained with Hoechst 33342 (2mgml
 1) and examined
with a fluorescence microscope, under UV light. BN cells with MN
were counted within two independent experiments involving at
least triplicates of 500 cells.
Statistics Statistical analysis was done using the unpaired t-test.
RESULTS AND DISCUSSION
We have investigated and compared in vitro apoptosis induction
and MN formation in p53 mutated 9L or p53 wild-type C6 cells
treated either by irradiation or by chemotherapeutic agents
(chosen according to their opposite efficacies on tumour cell
viability, data not shown). Apoptosis was quantified by relevant
tests addressing different stages of the process: measure of
caspase-3 activity (Figure 1A and C) and externalisation of
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Figure 1 In vitro induction of apoptosis or MN formation after chemo-
or radiotherapy. Measure of caspase-3 activity in 9L (A) and C6 (C) cells.
Measure of PS externalisation by AnnexinV–FITC binding assay on 9L (B)
and C6 cells (D). Total percentages of 9L (E) and C6 (F) binucleated cells
with MN. Significantly different from the control: *Po0.05, **Po0.01.
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MN assay
Cisplatin 1 mg kg−1
Irradiation 20 Gy
Control
1 MN 2 MN 3 MN > 4 MN
85 ± 6
73 ± 14
57 ± 10
13 ± 2
18 ± 3
21 ± 2
2 ± 1
7 ± 2
13 ± 0.5
0
2 ± 2
9 ± 2
A
B
C
Figure 2 In vivo induction of apoptosis or MN formation in 9L tumours
after local g-irradiation or systemic injection of cisplatin. TUNEL assay on
tumour section from control nontreated rat (A), cisplatin (1mg/kg
 1)t r e a t e d
rat (B)o rl o c a l l yg-irradiated rat (C). Total percentages of binucleated (BN)
cells with MN (D) in 9L tumours. Percentages of BN cells with MN divided
into subcategories depending on the number of MN per cell (E). *Significantly
different from the control (Po0.05). Magnification bars¼0.1mm.
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D). Results show, in general, similar induction of apoptosis in 9L
or C6 cells. Irradiation and mitomycin C at 3mgml
 1 were the best
inducers in both the cell lines and cisplatin at 3mgml
 1 quite less
effective. Our results are in agreement with the model in which
p53 ‘senses’ DNA damage through direct interaction with
DNA-damage sites, and then triggers downstream events leading
to apoptosis if the damages are not repaired (Bennett, 1999).
Especially, in C6 cells expressing the wild-type p53 protein, hardly
any apoptosis was observed after 24h, increasing with drug
concentration and with time. In 9L cells expressing a mutated form
of p53, alternative p53-independent pathways of apoptosis could
be active, implicating proteins such as p73 (Catani et al, 2002).
On the other hand, MN assays were more discriminatory to
detect DNA damage in relation to the p53 status of the tumour
cells. Indeed, emergence of BN cells with MN was quite high in 9L
cells with a mutated p53 gene (Figure 1E) and quite low in C6 cells
expressing the wild-type p53 (Figure 1F). Cisplatin at 10mgml
 1
and g-irradiation provoked even such damage in 9L cells that four,
five or six MN were often detected per cell, which is unusual (data
not shown). On the contrary, in C6 cells, more than three MN per
cell were observed rarely (data not shown). The emergence of MN
is attributed to the ability of cytotoxic agents to provoke DNA
strand breaks either directly as for irradiation or indirectly as the
results of drug insertion into the DNA helix (Brabec, 2002). Our
data fit with previous observations showing the importance of
wild-type p53 protein expression in the balance between cell cycle
arrest/DNA repair and apoptosis induction (Ferreira et al, 1999).
Indeed, very few MN were detectable in C6 cells. On the contrary,
in p53-mutated 9L cells, there is less growth arrest or DNA repair
and therefore a higher emergence of MN, as described for head and
neck carcinoma cells transfected with a mutant p53 (Masunaga
et al, 2002).
In vivo induction of apoptosis in established 9L tumours was
assessed after local tumour irradiation (20Gy) or systemic
injection of a nontoxic dose of cisplatin (1mgkg
 1) (Burger et al,
2002). Data from TUNEL assays (Figure 2A–C) and from anti-
active caspase-3 immunostaining (data not shown) revealed the
presence of apoptotic cells only after irradiation but not after
cisplatin treatment. However, by the MN assay, DNA damages
were detected in the same in vivo treated 9L tumours also after
chemotherapy. Indeed, as shown in Figure 2D, similar emergence
of total BN cells with MN was observed for both treatments, even if
the number of BN cells bearing X3MN per cell was increased in
the case of g-irradiation (Figure 2E). This result contrasts with the
conclusion of apoptosis tests. However, due to the in vivo
clearance of apoptotic cells by macrophages, there was no means
to quantify the time-dependent accumulation of apoptotic cells
(Savill and Fadok, 2000).
The MN assay is generally used to determine the in vivo
genotoxicity of carcinogens in normal cells like human hympho-
cytes (Gonzalez Borroto et al, 2001; Migliore et al, 2002). Only a
few recent publications reported MN formation in cell lines
derived from tumours (Truter et al, 2002). We have thus
successfully applied this technique on a solid tumour, to evaluate
its in vivo sensitivity to chemotherapy, assessing the real effect of
the drug on the tumour mass rather than a systemic toxicity.
Correlating apoptosis induction and MN formation could help to
set up new promising strategies of immunotherapy, combining
dendritic cell vaccination with radio- or chemotherapy as
producing sources of tumour antigens.
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